A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 2
Completed
- Conditions
- Heterozygous Familial Hypercholesterolemia
- Interventions
- Registration Number
- NCT04173793
- Lead Sponsor
- Akeso
- Brief Summary
This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of AK102 in patients with heterozygous familial hypercholesterolemia (HeFH).The primary objective of this study is to evaluate the efficacy of AK102 in patients with HeFH.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 109
Inclusion Criteria
- Subjects with heterozygous familial hypercholesterolemia diagnosed by genetic confirmation or clinical diagnosis criteria.
- Stable on pre-existing, lipid-lowering therapies (statins with or without ezetimibe) for at least 4 weeks with no planned medication or dose change for the duration of study participation.
- Fasting Low-Density Lipoprotein Cholesterol (LDL-C) ≥ 70 mg/dL in patients with history of Atherosclerotic Cardiovascular Disease (ASCVD) or Fasting Low-Density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL in patients without history of Atherosclerotic Cardiovascular Disease (ASCVD).
- Fasting triglycerides ≤ 400 mg/dL.
- Body weight ≥ 40kg.
Key
Exclusion Criteria
- Subjects with homozygous FH (clinically or by genotyping).
- Receipt of LDL apheresis within 12 months prior to the first dose of Investigational product.
- Receipt of Lomitapide or Mipomersen within 5 months prior to the first dose of Investigational product.
- Prior use of PCSK9 inhibitors.
- Creatine kinase (CK) >3 times of the upper limit of normal (ULN).
- Aspartate Aminotransferase (AST) ≥ 2 x ULN.
- Estimated Glomerular Filtration Rate (eGFR)≤ 30 mL/min/1.73m^2.
- Thyroid-Stimulating Hormone (TSH)> 1.5 x ULN or <1 x LLN.
- Type 1 diabetes, or type 2 diabetes that is or poorly controlled（HbA1c> 8.5%).
- Subjects with untreated or active chronic hepatitis B or active hepatitis C virus infections.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description AK102 150 mg AK102 Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks AK102 450 mg AK102 Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks AK102 450 mg Statins and/or Ezetimibe Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks AK102 300 mg AK102 Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks AK102 300 mg Statins and/or Ezetimibe Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks Placebo Q4W Statins and/or Ezetimibe Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks Placebo Q2W Placebo Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks Placebo Q2W Statins and/or Ezetimibe Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks AK102 150 mg Statins and/or Ezetimibe Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks Placebo Q4W Placebo Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
- Primary Outcome Measures
Name Time Method Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 12 At baseline and week 12
- Secondary Outcome Measures
Name Time Method Percent change from baseline in Total Cholesterol(TC) From baseline through 12 weeks Incidence of treatment-emergent adverse events From baseline through 12 weeks Serum concentrations of AK102 From baseline through 12 weeks Percent change from baseline in Apolipoprotein A-I (ApoA-I) From baseline through 12 weeks Percent change from baseline in Lipoprotein(a) [Lp-(a)] From baseline through 12 weeks Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) From baseline through 12 weeks Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) From baseline through 12 weeks Percent change from baseline in non High-density lipoprotein (non-HDL) cholesterol From baseline through 12 weeks Percent change from baseline in serum Triglyceride (TG) cholesterol From baseline through 12 weeks Number of subjects who develop detectable anti-drug antibodies (ADAs) From baseline through 12 weeks The immunogenicity of AK102 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies.
Percent change from baseline in high-density lipoprotein cholesterol (HDL-C) From baseline through 12 weeks Percent change from baseline in Apolipoprotein B (Apo B) From baseline through 12 weeks
Trial Locations
- Locations (2)
Beijing Anzhen Hospital
🇨🇳Beijing, Beijing, China
Peking Union Medical College Hospital
🇨🇳Beijing, China